Log In
BCIQ
Print this Print this
 

CBT-101

  Manage Alerts
Collapse Summary General Information
Company CBT Pharmaceuticals Inc.
DescriptionOral c-Met inhibitor targeting the epithelial to mesenchymal transition (EMT) pathway
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)
Mechanism of Actionc-Met receptor tyrosine kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today